Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc., No. 24-1965 (Fed. Cir. Jan. 29, 2025)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Regeneron Pharmaceuticals, Inc. holds Biologics Li- cense Application (BLA) No. 125387—approved by the Food and Drug Administration (FDA) —for EYLEA®, a therapeutic product that contain s the fusion protein aflibercept. Aflibercept is known as a “ VEGF antagonist” or “VEGF trap” due to its ability to bind, or “trap,” a protein called vascular endothelial growth factor (VEGF) before VEGF can bind to receptors in the human body and stimu- late blood -vessel growth.